9 is NOT enough!

AUTHOR: David Oarr In June, I traveled to Washington D.C. where I joined more than 700 pancreatic cancer patients and advocates on the Hill.¬† We met with congressmen and senators, and we collectively proclaimed that a 9 percent¬† five-year-survival rate is NOT GOOD ENOUGH. In between events and running from one congressional office to another,…

Attacking Metastatic Breast Cancer

CytImmune wants to help individuals living with metastatic breast cancer live longer and maintain a high quality of life. We hope you will support our efforts to advance our technology through a Phase II clinical trial.

Shooting for 95%

We have created a nanotechnology based cancer therapy that we believe is capable of delivering a 95% response rate to solid tumor cancer patients. Why are we so confident? Because it’s already been done. SOME BACKGROUND A characteristic of the micro-environment in all solid tumors, and a primary driver of cancer therapy failures, is high…

Treat Every Cancer like Metastatic Cancer

Cancer patients deserve a better outcome and an opportunity to take control of their disease. For most cancer patients, control means proactively preventing recurrence. For metastatic cancer patients, control means converting their cancer into a chronic, manageable illness. The solution starts by treating all cancers as metastatic cancers, and then designing therapies to solve that problem.